SCHEMBL800193

SCHEMBL800193

CCCCCN(C)CCC

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 3/20 0.55
S1PR2 O95136 1/20 0.52
S1PR1 P21453 1/20 0.52
S1PR3 Q99500 1/20 0.52
S1PR5 Q9H228 1/20 0.52
SIGMAR1 Q99720 1/20 0.48
GGPS1 O95749 4/20 0.47
FDPS P14324 1/20 0.47
AGTR1 P30556 1/20 0.47
OPRM1 P35372 1/20 0.47
PDE3A Q14432 1/20 0.47
CHRM2 P08172 1/20 0.46
KDM5A P29375 3/20 0.44
KDM4C Q9H3R0 3/20 0.44
KDM5C P41229 1/20 0.44
KDM5B Q9UGL1 1/20 0.44
PHF8 Q9UPP1 1/20 0.42
TSHR P16473 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11870492 0.97 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL22654 0.97 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL117987 0.97 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL20298464 0.97 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL4869710 0.97 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL516694 0.97 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL8625464 0.97 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL15407868 0.97 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5
Hydrochloric Acid SCHEMBL22771820 0.97 DNM1 (0.57) DNM1S1PR2S1PR1S1PR3S1PR5
SCHEMBL15535338 0.97 DNM1 (0.60) DNM1S1PR2S1PR1S1PR3S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106745845-A A kind of Seawater Treatment antisludging agent and preparation method thereof 江苏经纬技术创新咨询有限公司 2017-05-31 CN claimed
WO-2008109780-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC (US) 2008-09-12 WO claimed
US-20080221070-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION 2008-09-11 US claimed
EP-0850086-A1 DEVICE FOR THE IONTOPHORETIC ADMINISTRATION OF BISPHOSPHONATES Becton, Dickinson and Company (US) 1998-07-01 EP claimed
US-5730715-A BONE DISORDERS BECTON DICKINSON AND COMPANY (US) 1998-03-24 US claimed
WO-1997047356-A1 DEVICE FOR THE IONTOPHORETIC ADMINISTRATION OF BISPHOSPHONATES BECTON, DICKINSON AND COMPANY (US) 1997-12-18 WO claimed
WO-2023189799-A1 SELF CROSS-LINKABLE POLYMER AND RESIST UNDERLAYER FILM-FORMING COMPOSITION 日産化学株式会社 2023-10-05 WO disclosed
WO-2022261235-A1 NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2022-12-15 WO disclosed
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-10-27 US disclosed
US-20190248881-A1 TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING PRECITHERA, INC. (CA) 2019-08-15 US disclosed
EP-3509156-A1 ELECTROLYTE SOLUTION DAIKIN INDUSTRIES, LTD. (JP) 2019-07-10 EP disclosed
EP-2631980-B1 NON-AQUEOUS ELECTROLYTE SOLUTION DAIKIN IND LTD (JP) 2017-10-11 EP disclosed
US-9745302-B2 10H-benzo[g]pteridine-2,4-dione derivatives, method for the production thereof, and use thereof TRIOPTOTEC GMBH (DE) 2017-08-29 US disclosed
US-7214818-B2 Method for synthesizing bisphosphonate HOFFMANN-LA ROCHE INC. (US) 2007-05-08 US disclosed
EP-0850086-A1 DEVICE FOR THE IONTOPHORETIC ADMINISTRATION OF BISPHOSPHONATES Becton, Dickinson and Company (US) 1998-07-01 EP disclosed
US-5730715-A BONE DISORDERS BECTON DICKINSON AND COMPANY (US) 1998-03-24 US disclosed
WO-1997047356-A1 DEVICE FOR THE IONTOPHORETIC ADMINISTRATION OF BISPHOSPHONATES BECTON, DICKINSON AND COMPANY (US) 1997-12-18 WO disclosed
EP-0052016-B1 CARBOSTYRIL COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-09-05 EP disclosed
US-4414390-A CARDIOTONIC AGENTS OTSUKA, PHARMACEUTICAL CO., LTD. (JP) 1983-11-08 US disclosed
EP-0052016-A1 Carbostyril compounds, compositions containing same and processes for preparing same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1982-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221070-A1 METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH SHBG, ESRRA, ESRRG DNM1 1865/4885S1PR2 928/4885S1PR1 981/4885
US-20220340570-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 DNM1 4044/4885S1PR2 2608/4885S1PR1 2230/4885
US-20190248881-A1 TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING TGFBR1, TGFBR2, SMAD2 DNM1 561/4885S1PR2 1933/4885S1PR1 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.